148 related articles for article (PubMed ID: 6926923)
21. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.
Kelsey FO
Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617
[No Abstract] [Full Text] [Related]
22. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Oct; 4(5):288-9. PubMed ID: 6096409
[No Abstract] [Full Text] [Related]
23. Response to comments on the proposed model of a professional drug label.
Martinez MN; Brown SA; Copeland DD; Haibel GK; Koritz GD; Riddell MG; Riviere JE; Rollins LD
J Am Vet Med Assoc; 1996 Dec; 209(12):2068-70. PubMed ID: 8960188
[No Abstract] [Full Text] [Related]
24. How does the FDA affect you and your practice?
Novitch M
Leg Aspects Med Pract; 1979 Mar; 7(3):23-6. PubMed ID: 423685
[No Abstract] [Full Text] [Related]
25. FDA in hot water again over cost of proposed drug labeling rule.
Demkovich LE
Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
[No Abstract] [Full Text] [Related]
26. Preparing for an FDA audit.
Barnes D
Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
[No Abstract] [Full Text] [Related]
27. New prescription for drug regulation.
Pines WL
FDA Consum; 1978 Jun; 12(5):7-10. PubMed ID: 10308117
[TBL] [Abstract][Full Text] [Related]
28. The history of patient package inserts in the United States.
Moore SR; Morris LA; Groft SC
Can Pharm J; 1981 May; 114(5):173-5. PubMed ID: 10251273
[No Abstract] [Full Text] [Related]
29. AVMA legislation: partial solution to drug availability problem.
Gloyd JS
J Am Vet Med Assoc; 1993 Apr; 202(7):1055-6. PubMed ID: 8473213
[No Abstract] [Full Text] [Related]
30. Prescription drug products; patient labeling requirements: proposed rule.
Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
[No Abstract] [Full Text] [Related]
31. Scientific basis for nonapproved use of drugs in veterinary practice.
Brumbaugh GW
J Am Vet Med Assoc; 1993 May; 202(10):1693-6;discussion 1713-7. PubMed ID: 8514586
[No Abstract] [Full Text] [Related]
32. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
[TBL] [Abstract][Full Text] [Related]
33. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1987 Aug; 7(4):268-9. PubMed ID: 3624511
[No Abstract] [Full Text] [Related]
34. Drug information to contain NAC study results.
Pa Med; 1972 Jul; 75(7):20. PubMed ID: 5032310
[No Abstract] [Full Text] [Related]
35. Wyeth preemption case ruling sparks labeling confusion.
Allison M
Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
[No Abstract] [Full Text] [Related]
36. Mandatory PPIs to begin in 1981; APhA issues strong objections.
Small WE
Am Pharm; 1980 Nov; NS20(11):10-1. PubMed ID: 7457342
[No Abstract] [Full Text] [Related]
37. A survey of developments in food and drug law from July 1998 to November 1999.
Littlefield N; Hada NR
Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
[No Abstract] [Full Text] [Related]
38. FDA acts on estrogen, progestin labeling.
FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006
[No Abstract] [Full Text] [Related]
39. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1987 Jun; 7(3):185-6. PubMed ID: 3597806
[No Abstract] [Full Text] [Related]
40. Relative efficacy.
J Okla State Med Assoc; 1973 Mar; 66(3):115-20. PubMed ID: 4689645
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
